Atlas Trials

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Clinical trial NCT05833763 · RECRUITING

Trial details

NCT number
NCT05833763
Sponsor
Australasian Leukaemia and Lymphoma Group
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell LymphomaMantle Cell Lymphoma Refractory
Start date
2023-10-12
Primary completion
2032-04-01
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.